Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Shizuoka Cancer Center Hospital, Shizuoka, Japan

Survival: 14.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: Japan
City/State/Province: Shizuoka
Hospital: Shizuoka Cancer Center Hospital
Journal: Link
Date: 8/2006

Patients: This phase II study involved 128 patients with stage IIIB or IV non-small cell lung cancer. These patients were randomly divided into two groups of 64, GC and GV. The median age of the GC group was 60, and there were 43 men and 21 women. The median age of the GV group was 62, and there were 42 men and 22 women. Eighteen people from group GC and 27 from group GV had a history of smoking.

Treatment: Group GC was treated with the chemotherapy drugs gemcitabine and carboplatin. Group GV received the chemotherapy drugs gemcitabine and vinorelbine.

Toxicity: Grade 4 hematological toxicities (such as leucopenia, neutropenia, anemia, and thrombocytopenia) occurred in 45.3% of the GC group and 25.8% of the GV group. Grade 3 or 4 non-hematological toxicities (such as nausea, emesis, fatigue, diarrhea, constipation, rash, phlebitis, and pneumonitis) occurred in 19.4% of the GV group and 7.8% of the GC group.

Results: The median survival was 14.2 months (432 days reported by the authors) in the GC group and 12.7 months (385 days reported by the authors) in the GV group.

Correspondence: Nobuyuki Yamamoto, M.D.

E-mail to a Friend Email Physician More Information